EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host ...

Patients who were systemic therapy-naïve and received upadacitinib 15 mg or 30 mg and those who were systemic therapy-experienced and received upadacitinib 30 mg experienced sustained effectiveness ...

Background: Upadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are ...

Get Instant Summarized Text (Gist) Male patients with inflammatory bowel disease (IBD) have an increased risk of ischemic heart diseases (IHDs), with a composite hazard ratio of 1.98 compared to ...

including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.